Analyst Rating Coverage
Morningstar(Rank #127), a leading investment research and analysis firm, has maintained its “Buy” rating on Tilray’s stock, a Canadian cannabis company, with a 12-month target price of $9 per share. This rating and target price reflect Morningstar’s positive outlook on Tilray’s prospects and its belief that the stock represents an attractive investment opportunity for investors.
Tilray is a global cannabis company that focuses on medical cannabis, cannabis-derived pharmaceuticals, and cannabis-based consumer products. The company operates in several countries, including Canada, the United States, Germany, Portugal, and Australia, and has a diverse product portfolio that includes medical cannabis products, CBD products, and beverages. Tilray also has a strong presence in the recreational cannabis market in Canada, where it offers a wide range of cannabis products.
Morningstar’s Buy rating on Tilray is based on several factors. First, the firm believes that Tilray is well-positioned to benefit from the growing global cannabis market. With increasing legalization of cannabis for medical and recreational use in various countries, there is a significant growth opportunity for Tilray to expand its market share and revenue. The company’s diversified operations in multiple countries also provide it with a global footprint, which can help mitigate risks associated with regulatory changes in any one country.
Second, Morningstar highlights Tilray’s strong partnerships and strategic alliances as a positive factor. Tilray has secured several key partnerships and collaborations with established companies, including pharmaceutical giant Novartis, beverage company AB InBev, and global cannabis company Canndoc, among others. These partnerships provide Tilray with access to distribution networks, research and development capabilities, and expertise in various areas, which can help accelerate its growth and expansion.
Third, Morningstar notes Tilray’s efforts to improve its financials and operational efficiency. The company has been focused on reducing its operating expenses, improving its gross margins, and increasing its production capacity. Tilray has also been working towards achieving positive cash flow and profitability, which are critical factors for the long-term sustainability of any company. Morningstar views these efforts positively and believes that Tilray’s financial performance is likely to improve over time.
Morningstar considers the valuation of Tilray’s stock as attractive. With a 12-month target price of $9 per share, Morningstar believes that the stock is trading at a discount to its intrinsic value. The target price represents a significant upside potential from the current market price, which indicates that Morningstar sees Tilray as undervalued and expects the stock to outperform in the coming months.
Morningstar’s Buy rating on Tilray with a 12-month target price of $9 per share reflects the firm’s positive outlook on Tilray’s prospects. The company’s global presence, strategic partnerships, efforts to improve financials and operational efficiency, and attractive valuation are the key factors supporting Morningstar’s rating.
TLRY Stock Forecast & Analysis
The average analyst target price for Tilray Inc, based on forecasts from 6 analysts, is CAD 7.46 over the next 12 months. The average analyst rating is Strong Buy. Stock Target Advisor’s analysis of Tilray Inc is Neutral, considering 5 positive signals and 5 negative signals. Tilray Inc’s stock price at the last closing was CAD 3.38, with a change of +0.90% over the past week, +0.90% over the past month, and -58.12% over the last year.